Article
Pharmacology & Pharmacy
Qian Zhang, XiangTing Chen, FeiFei Chen, SiYuan Wen, ChangQing Zhou
Summary: Compared with levodopa, dopamine agonists (DAs) as initial treatment are associated with lower incidences of motor complications in early Parkinson's disease (PD). There is no strong evidence that a given DA is more potent in lower incidences of motor complications than another. We performed a network meta-analysis of levodopa versus DAs as monotherapy in early PD to assess the risk of motor complications.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Article
Clinical Neurology
Sara C. Staubo, Ole Martin Fuskevag, Mathias Toft, Ingeborg H. Lie, Kirsti M. J. Alvik, Pal Jostad, Stein H. Tingvoll, Hallvard Lilleng, Kristina Rosqvist, Elisabet Storset, Per Odin, Espen Dietrichs, Erik Sveberg Dietrichs
Summary: The study suggests that the occurrence of impulse control disorders (ICDs) among patients using ropinirole is dependent on serum concentration and drug exposure, while the use of pramipexole may inherently increase ICD risk.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Neurosciences
Jeremy Cousineau, Valentin Plateau, Jerome Baufreton, Morgane Le Bon-Jego
Summary: This article reviews the impact of dopamine depletion on the circuitry of the primary motor cortex (M1) in Parkinson's disease (PD) through studies in PD patients and animal models. The authors summarize the importance of dopamine in M1 physiology and discuss the effects of PD treatments on M1 functions.
NEUROBIOLOGY OF DISEASE
(2022)
Review
Neurosciences
Xiao-Zhong Jing, Hui-Jia Yang, Reyisha Taximaimaiti, Xiao-Ping Wang
Summary: Dopamine (DA) agonists are excellent dopamine replacement therapy for Parkinson's disease (PD) patients and are crucial in controlling motor and non-motor symptoms. Each DA agonist has unique characteristics, efficacy, and safety profile. Understanding DA agonists helps clinicians balance clinical efficacy and side effects.
CURRENT NEUROPHARMACOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Syed Awais Ali Zaidi, Mahtab Ahmad Khan, Muhammad Rizwan Khan, Hammad Ahmed, Zaib Ali Shahryar, Muhammad Umar Khayam Sahibzada, Saad Alghamdi, Abdulelah Aljuaid, Mazen Almehmadi, Mamdouh Allahyani
Summary: Parkinson's disease is a progressive neurological disorder that affects movement. This study found that Benzoic-D5 shows potential in ameliorating the symptoms of Parkinson's disease in mice.
ARABIAN JOURNAL OF CHEMISTRY
(2023)
Article
Clinical Neurology
Victor Abler, Cecilia Brain, Clive Ballard, Ana Berrio, Bruce Coate, Alberto. J. J. Espay
Summary: The study found that Pimavanserin 34 mg was well tolerated and did not have a negative impact on motor or cognition in patients with PD psychosis. Rates of motor- and cognition-related adverse events were similar between Pimavanserin and placebo.
FRONTIERS IN NEUROLOGY
(2022)
Review
Biochemistry & Molecular Biology
Luca Magistrelli, Marco Ferrari, Alessia Furgiuele, Anna Vera Milner, Elena Contaldi, Cristoforo Comi, Marco Cosentino, Franca Marino
Summary: Parkinson's disease is a neurodegenerative disorder caused by loss of dopaminergic neurons. Treatment relies on dopaminergic replacement, but genetic factors can influence the clinical progression and drug response in patients. Understanding the genetic variability of dopaminergic receptors may provide insights into the development of personalized therapies for PD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Si-Chun Gu, Qing Ye, Chang-De Wang, Shao-Rong Zhao, Jie Zhou, Chen Gao, Yu Zhang, Zhen-Guo Liu, Can-Xing Yuan
Summary: Pingchan granule (PCG) has a long-lasting and extensive symptomatic efficacy for both motor and non-motor symptoms of Parkinson's disease (PD) with good tolerance.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Clinical Neurology
Marina Picillo, Onanong Phokaewvarangkul, Yu-Yan Poon, Cameron C. McIntyre, Sinem Balta Beylergil, Renato P. Munhoz, Suneil K. Kalia, Mojgan Hodaie, Andres M. Lozano, Alfonso Fasano
Summary: This study compared the efficacy and safety of levodopa versus dopamine agonist monotherapy after deep brain stimulation in Parkinson's disease. Results showed that in short- and mid-term follow-up, more than half of patients were able to safely continue monotherapy, with levodopa patients having a higher likelihood. In the long term, only a minority of patients were able to maintain levodopa monotherapy, while dopamine agonist monotherapy was not well tolerated.
MOVEMENT DISORDERS
(2021)
Article
Neurosciences
Daniele Urso, Lucia Batzu, Giancarlo Logroscino, K. Ray Chaudhuri, Joana B. Pereira
Summary: This study investigated the potential of cerebrospinal fluid (CSF) and serum neurofilament light (NfL) levels as biomarkers for predicting the progression of nonmotor symptoms (NMS) in Parkinson's disease (PD) patients. The findings showed that both CSF and serum NfL levels were associated with the progression of depression and anxiety in PD patients, with serum NfL showing stronger associations with NMS.
NEUROBIOLOGY OF DISEASE
(2023)
Article
Clinical Neurology
Adam Fry, Dharampreet Singh, Louis Manganas, Marc L. Gordon, Christopher Christodoulou, Hoi-Chung Leung, Guy J. Schwartz
Summary: This study found a high incidence of temporal lobe epileptiform discharges in Parkinson's disease patients with visual hallucinations compared to those without. This finding suggests a possible association with a epileptogenic focus in the visual cortex and highlights the potential use of antiepileptic drugs in treatment-refractory patients, similar to Charles Bonnet syndrome, temporal lobe epilepsy, and migraine with visual aura.
FRONTIERS IN NEUROLOGY
(2022)
Editorial Material
Neurosciences
Mariah J. Lelos
Summary: Advanced therapeutic medicinal products (ATMPs), including cell and gene therapies, are being developed for Parkinson's disease with the goal of replacing lost dopamine and improving motor dysfunctions. However, the impact of these interventions on cognitive symptoms is still unclear. There is evidence that certain cognitive processes dependent on dopamine can be modulated by dopamine medications, but limited data is currently available on how cell and gene ATMPs may influence these symptoms.
JOURNAL OF INTEGRATIVE NEUROSCIENCE
(2022)
Article
Clinical Neurology
Hidetomo Murakami, Motohiro Okumura, Masakazu Ozawa, Masahiro Mimori, Takahiro Maku, Tomotaka Shiraishi, Tomomichi Kitagawa, Hiroki Takatsu, Takeo Sato, Teppei Komatsu, Kenichiro Sakai, Tadashi Umehara, Shusaku Omoto, Hidetaka Mitsumura, Yasuyuki Iguchi
Summary: This study investigated the relationship between the efficacy of monotherapy with MAO-B inhibitors on motor symptoms in patients with Parkinson's disease and baseline cognitive function. The results showed that higher FAB scores were associated with improved motor symptoms, suggesting a higher activity of endogenous dopamine.
NEUROLOGICAL SCIENCES
(2023)
Review
Psychology, Clinical
Bodyl A. Brand, Yudith R. A. Haveman, Franciska de Beer, Janna N. de Boer, Paola Dazzan, Iris E. C. Sommer
Summary: There are significant differences between men and women in the efficacy and tolerability of antipsychotic drugs. Women have slower drug absorption, metabolism, and excretion, leading to higher plasma levels and increased risk for side-effects. Current treatment guidelines are based on studies predominantly conducted in men, which may result in overmedication of women. Women also have higher dopamine receptor occupancy compared to men, necessitating dose adjustments at different hormonal phases.
PSYCHOLOGICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Elias D. Mouchlianitis, Lucy D. Vanes, Derek K. Tracy, Anne-Katherin Fett, Daniel Joyce, Sukhi S. Shergill
Summary: Glutamatergic dysfunction is associated with treatment resistance in individuals with schizophrenia. This study used neurochemical and functional brain imaging methods to investigate glutamatergic dysfunction and reward processing in treatment-resistant and treatment-responsive schizophrenia. The results suggest that glutamatergic differences can differentiate treatment-resistant and treatment-responsive schizophrenia, which has potential diagnostic value.
SCIENTIFIC REPORTS
(2023)